Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · Sep 9, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how an automatic surveillance system can help monitor patients who have gastric premalignant lesions, which are abnormal changes in the stomach that could lead to cancer in the future. The study will compare three different groups of patients: one group will receive reminders through an intelligent system, another group will get manual reminders from healthcare providers, and the third group will not receive any reminders. By observing how well these groups are monitored over time, researchers hope to find out if the automatic system improves the surveillance rate.

To be eligible for this trial, participants need to be at least 18 years old and scheduled for an upper endoscopy, a procedure that allows doctors to look inside the stomach. However, individuals with certain conditions, such as specific types of cancer or those who have had previous surgeries on the stomach or esophagus, may not qualify. If you join the trial, you can expect to be part of a system that aims to enhance the follow-up care for your condition, potentially leading to better health outcomes. Additionally, the trial is currently recruiting participants, so there's an opportunity for those interested to get involved.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female aged 18 years or older who undergo upper endoscopy.
• Exclusion Criteria:
• • 1)No contact information or invalid contact information.
• • 2) The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on.
• • 3) Needless for surveillance or others.
• • 4) High-grade intraepithelial neoplasia or cancer of the esophagus or stomach.
• • 5) Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus.
• • 6) High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.